Results 101 to 110 of about 811,174 (190)

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie   +4 more
wiley   +1 more source

BTK Inhibitor [PDF]

open access: yes, 2020
WANG XUEHAI   +27 more
openaire   +3 more sources

Scalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.
Keenan Ernste   +9 more
wiley   +1 more source

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis

open access: yesDrug Design, Development and Therapy, 2022
Edgar Carnero Contentti,1 Jorge Correale2,3 1Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina; 2Department of Neurology, Fleni, Buenos Aires, Argentina; 3Universidad de Buenos Aires-CONICET, Instituto de ...
Carnero Contentti E, Correale J
doaj  

Salicylic Acid as a Food‐Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation‐Predominant IBS

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Tiaoqi Daozhi Decoction (TQDZD) is a classic formulation composed of eight medicine‐food homologous botanicals. UPLC‐MS/MS profiling identified 1962 non‐redundant compounds in its aqueous extract, predominantly phenolic acids and flavonoids, of which 107 metabolites were systemically bioavailable.
Min Duan   +4 more
wiley   +1 more source

''From Molecular Resistance to Tumor Evolution: Insights in BTK Inhibitors, Tumor Microenvironment and Genetic Variants.''

open access: yes
reservedBruton’s tyrosine kinase (BTK) prevails as a key mediator in the elaborate system of immune signaling, with its essential role in maintaining homeostasis of the B lymphocyte compartment.
RUSTEMI, BRISEJDA
core  

A Review on Chemical Components, Metabolism, Modern Pharmacological Actions and Food Application Prospects of Pueraria lobata, a Medicine‐Food Homologous Chinese Materia Medica

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Pueraria lobata (PL) accumulates isoflavones, polysaccharides, and triterpenoids. Absorption, distribution, metabolism, and excretion (ADME) modulate the bioavailability of these bioactive constituents and govern their health‐promoting effects, including cardioprotection, glycemic regulation, antioxidation, anti‐inflammation, and antitumor activity ...
Jia Liu   +7 more
wiley   +1 more source

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and Perspectives

open access: yes
The introduction of Bruton tyrosine kinase inhibitors (BTKis) has significantly improved prognosis in the treatment of MCL. BTK inhibitors have demonstrated strong activity in the treatment of relapsed/refractory patients with mantle cell lymphoma (MCL),
Tadeusz Robak   +2 more
core   +1 more source

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk

open access: yes, 2018
Btk is an attractive target for the treatment of a range of Bcell malignancies as well as several autoimmune diseases such as murine lupus and rheumatoid arthritis.
Qiu, Hui (author)   +27 more
core   +1 more source

Home - About - Disclaimer - Privacy